30 results on '"Rovithi, Maria"'
Search Results
2. Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib
3. A multicenter phase I trial of metronomic oral vinorelbine plus cisplatin in patients with NSCLC
4. Second-line chemotherapy with Capecitabine (Xeloda) and Docetaxel (Taxotere) in previously treated, unresectable adenocarcinoma of pancreas: the final results of a phase II trial
5. Epithelial Transfer of the Tyrosine Kinase Inhibitors Erlotinib, Gefitinib, Afatinib, Crizotinib, Sorafenib, Sunitinib, and Dasatinib: Implications for Clinical Resistance
6. Abstract C079: Effect of food on the pharmacokinetics of high dose intermittent sunitinib in patients with advanced solid tumors
7. Taste Alterations During Treatment With Protein Kinase Inhibitors: A Pilot Study
8. Phase I Dose-Escalation Study of Once Weekly or Once Every Two Weeks Administration of High-Dose Sunitinib in Patients With Refractory Solid Tumors
9. Metastatic lung cancer in oral cavity: A case report and literature review.
10. Sorafenib administered using a high-dose, pulsatile regimen in patients with advanced solid malignancies: Results of a phase I exposure escalation study.
11. Development of bioluminescent chick chorioallantoic membrane (CAM) models from primary pancreatic cancer cells: A platform for drug testing
12. A phase 1/2 study of intermittent, high dose sunitinib in patients with advanced solid tumors.
13. Sorafenib administered using a high-dose, pulsatile regimen in patients with advanced solid malignancies: A phase I exposure escalation study.
14. Development of bioluminescent chick chorioallantoic membrane (CAM) models for primary pancreatic cancer cells: a platform for drug testing
15. High-dose, intermittent sunitinib as an alternative treatment strategy
16. Alternative scheduling of pulsatile, high dose sunitinib efficiently suppresses tumor growth
17. Response and toxicity prediction by MALDI-TOF-MS serum peptide profiling in patients with non-small cell lung cancer
18. Mass spectrometry-based phosphoproteomics of tumor needle biopsies from patients (pts) with advanced solid tumors during treatment with protein kinase inhibitors.
19. A phase 1 study of weekly high dose sunitinib in patients with advanced solid tumors: Early signs of activity in non-RCC tumor types.
20. Abstract 2989: High-dose, intermittent sunitinib as an alternative treatment strategy
21. Tumor, skin, and plasma concentrations of protein kinase inhibitors (PKIs) in patients with advanced cancer.
22. Abstract 1621: Short-time exposure to high concentrations of sunitinib causes tumor cell death.
23. A phase II study of metronomic oral vinorelbine administered in the second line and beyond in non-small cell lung cancer (NSCLC): a phase II study of the Hellenic Oncology Research Group
24. Response prediction by MALDI-TOF-MS serum peptide profiling of combination treatment with sorafenib and erlotinib in patients with non-small cell lung cancer.
25. Abstract 3608: Measurement of kinase activity in cancer cell lines and tumor tissue using a tyrosine kinase peptide substrate array
26. Abstract 1374: Cross-resistance and sensitivity of sunitinib resistant tumor cells
27. A multicenter phase I trial of metronomic oral vinorelbine plus cisplatin in patients with NSCLC
28. Second-line chemotherapy with Capecitabine (Xeloda) and Docetaxel (Taxotere) in previously treated, unresectable adenocarcinoma of pancreas: the final results of a phase II trial
29. Development of bioluminescent chick chorioallantoic membrane (CAM) models for primary pancreatic cancer cells: a platform for drug testing
30. Response and toxicity prediction by MALDI-TOF-MS serum peptide profiling in patients with non-small cell lung cancer.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.